1.92  0.03 (1.59%)		05-08 16:00
Open: 1.9 High: 1.93 Volume: 602,329		Pre. Close: 1.89 Low: 1.875 Market Cap: 165(M)

Short term
Mid term
Targets	6-month :	2.73	1-year :	3.19
Resists	First :	2.33	Second :	2.73
Pivot price	1.89
Supports	First :	1.74	Second :	1.37
MAs	MA(5) :	1.91	MA(20) :	1.94
	MA(100) :	1.82	MA(250) :	1.84
MACD	MACD :	0	Signal :	0
%K %D	K(14,3) :	37.7	D(3) :	30.9
RSI	RSI(14): 54.7
52-week	High :	3.05	Low :	1

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ MIST ] has closed below upper band by 41.7%. Bollinger Bands are 56.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	1.93 - 1.94	1.94 - 1.95
Low:	1.85 - 1.86	1.86 - 1.87
Close:	1.9 - 1.92	1.92 - 1.94

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans. The company was incorporated in 2003 and is headquartered in Montréal, Canada.

Wed, 06 May 2026
Biotech Milestone pairs May 13 results with investor webcast - Stock Titan

Thu, 30 Apr 2026
[ARS] Milestone Pharmaceuticals Inc. SEC Filing - Stock Titan

Thu, 30 Apr 2026
Milestone Pharmaceuticals (NASDAQ: MIST) to vote on equity plan and pay - Stock Titan

Thu, 23 Apr 2026
Milestone Pharmaceuticals (MIST) Proxy Filing Summary - Quartr

Thu, 16 Apr 2026
[144] Milestone Pharmaceuticals Inc. SEC Filing - Stock Titan

Tue, 27 Jan 2026
All You Need to Know About Milestone Pharmaceuticals (MIST) Rating Upgrade to Strong Buy - Yahoo Finance

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	118 (M)
Held by Insiders	1.407e+007 (%)
Held by Institutions	2.4 (%)
Shares Short	8,760 (K)
Shares Short P.Month	0 (K)

EPS	-6.203e+007
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	-1 %
Return on Assets (ttm)	116.2 %
Return on Equity (ttm)	-41.1 %
Qtrly Rev. Growth	1.55e+006 %
Gross Profit (p.s.)	0
Sales Per Share	-332.83
EBITDA (p.s.)	2.24638e+006
Qtrly Earnings Growth	-0.8 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	-49 (M)

PE Ratio	-0.01
PEG Ratio	0
Price to Book value	0
Price to Sales	-0.01
Price to Cash Flow	3.89

Dividend	0
Forward Dividend	1.033e+007
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.